<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516919</url>
  </required_header>
  <id_info>
    <org_study_id>DF-06-018</org_study_id>
    <nct_id>NCT00516919</nct_id>
  </id_info>
  <brief_title>Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons</brief_title>
  <official_title>Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Donaghue Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study designed to examine the effectiveness of an obesity medication
      (orlistat) given in addition to behavioral weight loss therapy. Participants will be obese
      monolingual (Spanish-speaking only) men and women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Participant BMI</measure>
    <time_frame>4 months and 6 month follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Body Mass Index (BMI)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Obesity</condition>
  <condition>Binge Eating</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xenical + behavioral intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo + behavioral intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenical + behavioral intervention</intervention_name>
    <description>120 mg TID; Behavioral weight loss in Spanish</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xenical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral intervention + placebo</intervention_name>
    <description>Behavioral weight loss treatment in Spanish Placebo TID</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Monolingual Spanish Speaking

          -  Obese (BMI &gt;= 30)

        Exclusion Criteria:

          -  Pregnancy

          -  Current cardiac disease

          -  Serious neurologic illnesses
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos M Grilo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hispanic Clinic of the Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Department of Psychiatry</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 7, 2013</lastchanged_date>
  <firstreceived_date>August 15, 2007</firstreceived_date>
  <firstreceived_results_date>July 31, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Carlos Grilo</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Psychology</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Binge Eating</keyword>
  <keyword>Monolingual Hispanic Persons</keyword>
  <keyword>Orlistat</keyword>
  <keyword>Behavioral Weight Loss Treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Binge-Eating Disorder</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled participants from August 2007 through October 2009. Participants were a consecutive series of 79 monolingual (Spanish-speaking-only) obese Latino/as recruited from clinical teams and referrals at a community mental health center serving economically disadvantaged persons with mental health needs.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Xenical + Behavioral Intervention</title>
          <description>Drug: Xenical + Behavioral: behavioral intervention
Xenical + behavioral intervention : 120 mg three times a day; Behavioral weight loss in Spanish</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Behavioral Intervention</title>
          <description>Drug: Placebo + Behavioral: behavioral intervention
Behavioral intervention + placebo : Behavioral weight loss treatment in Spanish Placebo three times a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Enrollment</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46.3" spread="9.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="65"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant BMI</title>
        <description>Body Mass Index (BMI)</description>
        <time_frame>4 months and 6 month follow-up</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data for all randomized participants were included. In the event of dropout or missing data, baseline values were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: Xenical + Behavioral: Behavioral Intervention</title>
            <description>Xenical + behavioral intervention
Xenical + behavioral intervention : 120 mg three times a day; Behavioral weight loss in Spanish</description>
          </group>
          <group group_id="O2">
            <title>Drug: Placebo + Behavioral: Behavioral Intervention</title>
            <description>Placebo + behavioral intervention
Behavioral intervention + placebo three times a day: Behavioral weight loss treatment in Spanish Placebo TID</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participant BMI</title>
            <description>Body Mass Index (BMI)</description>
            <units>kg/m^2</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Post-treatment (4 months)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.0" spread="5.9"/>
                  <measurement group_id="O2" value="36.4" spread="4.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6 month follow up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.3" spread="4.9"/>
                  <measurement group_id="O2" value="36.8" spread="4.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for group differences in BMI at post-treatment, controlling for baseline BMI.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>=0.51</p_value>
            <method>ANCOVA</method>
            <method_desc>Covariate = Baseline (pre-treatment) BMI; Degrees of freedom = (1, 76)</method_desc>
            <param_type>F statistic</param_type>
            <param_value>0.45</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for group differences in BMI at 6-month follow-up, controlling for baseline BMI.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>=0.41</p_value>
            <method>ANCOVA</method>
            <method_desc>Covariate = Baseline (pre-treatment) BMI; Degrees of freedom = (1, 76)</method_desc>
            <param_type>F statistic</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for the duration of the trial (through 4 months of active treatment).</time_frame>
      <desc>Overall frequency of reported side effects was only slightly higher for Xenical than for placebo, although reports of minor gastrointestinal events known to be due to Xenicalâ€™s mechanism of action were higher for the Xenical condition. Nearly all events occurred early in treatment, were generally mild, and resolved spontaneously.</desc>
      <group_list>
        <group group_id="E1">
          <title>Drug: Xenical + Behavioral: Behavioral Intervention</title>
          <description>Xenical + behavioral intervention
Xenical + behavioral intervention : 120 mg three times a day; Behavioral weight loss in Spanish</description>
        </group>
        <group group_id="E2">
          <title>Drug: Placebo + Behaviora: Behavioral Intervention</title>
          <description>Placebo + behavioral intervention
Behavioral intervention + placebo three times a day: Behavioral weight loss treatment in Spanish Placebo TID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carlos Grilo</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-785-2792</phone>
      <email>carlos.grilo@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
